TY - JOUR
T1 - Tuberculosis treatment and resulting abnormal blood glucose
T2 - a scoping review of studies from 1981 - 2021
AU - Williams, Victor
AU - Onwuchekwa, Chukwuemeka
AU - Vos, Alinda G
AU - Grobbee, Diederick E
AU - Otwombe, Kennedy
AU - Klipstein-Grobusch, Kerstin
N1 - Funding Information:
VW is supported by the Global Health PhD Support Programme at University Medical Center, Utrecht, The Netherlands. Dr Marie-Louise Goudeau, Librarian, Utrecht University Library, for reviewing the search terms and guiding the search process.
Publisher Copyright:
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022/9/30
Y1 - 2022/9/30
N2 - BACKGROUND: Hyperglycaemia is a risk factor for tuberculosis. Evidence of changes in blood glucose levels during and after tuberculosis treatment is unclear.OBJECTIVE: To compile evidence of changes in blood glucose during and after tuberculosis treatment and the effects of elevated blood glucose changes on treatment outcomes in previously normoglycaemic patients.METHODS: Original research studies (1980 to 2021) were identified in PubMed, Web of Science, CINAHL and Embase databases.RESULTS: Of the 1,277 articles extracted, 14 were included in the final review. All the studies were observational and 50% were prospective. Fasting blood sugar was the most common clinical test (64%), followed by the glycated haemoglobin test and the oral glucose tolerance test (each 50%). Most tests were conducted at baseline and in the third month of treatment. Twelve studies showed that the prevalence of hyperglycaemia in previously normoglycaemic patients decreased from baseline to follow-up and end of treatment. Three studies showed successful treatment outcomes of 64%, 75% and 95%. Patients with hyperglycaemia at baseline were more likely to develop cavitary lung lesions and poor treatment outcomes and had higher post-treatment mortality. There was no difference in outcomes by human immunodeficiency virus (HIV) status.CONCLUSION: Elevated blood glucose in normoglycaemic patients receiving treatment for tuberculosis decreased by the end of treatment. Positive HIV status did not affect glucose changes during treatment. Further research is needed to investigate post-treatment morbidity in patients with baseline hyperglycaemia and the effects of HIV on the association between blood glucose and tuberculosis.
AB - BACKGROUND: Hyperglycaemia is a risk factor for tuberculosis. Evidence of changes in blood glucose levels during and after tuberculosis treatment is unclear.OBJECTIVE: To compile evidence of changes in blood glucose during and after tuberculosis treatment and the effects of elevated blood glucose changes on treatment outcomes in previously normoglycaemic patients.METHODS: Original research studies (1980 to 2021) were identified in PubMed, Web of Science, CINAHL and Embase databases.RESULTS: Of the 1,277 articles extracted, 14 were included in the final review. All the studies were observational and 50% were prospective. Fasting blood sugar was the most common clinical test (64%), followed by the glycated haemoglobin test and the oral glucose tolerance test (each 50%). Most tests were conducted at baseline and in the third month of treatment. Twelve studies showed that the prevalence of hyperglycaemia in previously normoglycaemic patients decreased from baseline to follow-up and end of treatment. Three studies showed successful treatment outcomes of 64%, 75% and 95%. Patients with hyperglycaemia at baseline were more likely to develop cavitary lung lesions and poor treatment outcomes and had higher post-treatment mortality. There was no difference in outcomes by human immunodeficiency virus (HIV) status.CONCLUSION: Elevated blood glucose in normoglycaemic patients receiving treatment for tuberculosis decreased by the end of treatment. Positive HIV status did not affect glucose changes during treatment. Further research is needed to investigate post-treatment morbidity in patients with baseline hyperglycaemia and the effects of HIV on the association between blood glucose and tuberculosis.
KW - Diabetes
KW - human immunodeficiency virus
KW - hyperglycaemia
KW - impaired glucose tolerance
UR - http://www.scopus.com/inward/record.url?scp=85139093605&partnerID=8YFLogxK
U2 - 10.1080/16549716.2022.2114146
DO - 10.1080/16549716.2022.2114146
M3 - Review article
C2 - 36178364
SN - 1654-9880
VL - 15
SP - 1
EP - 11
JO - Global Health Action
JF - Global Health Action
IS - 1
M1 - 2114146
ER -